For the Inventor, By the Inventor

Enter assignee name

Redwood City, CA, United States of America

Coherus Biosciences, Inc.

USPTO Granted Patents = 76

% Expired Patents = 63.2

EPO Patents = 5

Trademarks = 2

Forward Citations = 762

Loading Chart...

Loading Chart...

22 inventors (with patents filed for the assignee):

Mark Cornell Manning (61 out of 85 patents)

Robert W Payne (35 out of 39 patents)

Brian P Murphy (20 out of 134 patents)

4. Douglas Farrar (6 out of 6 patents)

5. Tsutomu Arakawa (5 out of 20 patents)

6. Jun Liu (5 out of 46 patents)

7. Ela Puchacz (4 out of 4 patents)

8. James Russell Grove (4 out of 4 patents)

9. Christos Mantzoros (3 out of 3 patents)

10. Isaias Prado (3 out of 3 patents)

11. John Ogez (2 out of 2 patents)

12. Wenchang Ji (2 out of 2 patents)

13. Patrick Daniel Begley (2 out of 2 patents)

14. Elzbieta Wiktoria Puchacz (1 out of 2 patents)

15. Ryan Erik Holcomb (1 out of 15 patents)

Core Competencies:

Aflibercept

Adalimumab

Etanercept

Stable Formulations

Recombinant Proteins

Liver Disease

Lipodystrophy

Protein Aggregation

Sterile Injection Devices

Formulation Stabilization

High Purity

Perfusion Method

76 patents: Sort by Forward Citations

1. 11752225 - Systems and methods for producing sterile injection devices (2023-09-12),

2. 11667702 - Stable aqueous formulations of aflibercept (2023-06-06),

3. 11583584 - Stable protein compositions and methods of their use (2023-02-21),

4. 11576971 - Method of filling a container with no headspace (2023-02-14),

5. 11426446 - Stable aqueous formulations of aflibercept (2022-08-30),

6. 11400072 - Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy (2022-08-02),

7. 11396540 - Methods for making recombinant proteins (2022-07-26),

8. 11253508 - PPARy agonist for treatment of progressive supranuclear palsy (2022-02-22),

9. 11229702 - High concentration formulations of adalimumab (2022-01-25),

10. 11135267 - Etanercept formulations stabilized with metal ions (2021-10-05),

11. 11129876 - Etanercept formulations stabilized with amino acids (2021-09-28),

12. 11071782 - Method of filling a container with no headspace (2021-07-27),

13. 11001627 - Correctly folded etanercept in high purity and excellent yield (2021-05-11),

14. 11001623 - Method of manufacturing a protein by perfusion in media with a low amino acid concentration (2021-05-11),

15. 11000588 - Etanercept formulations stabilized with sodium chloride (2021-05-11),

Company Overview

Coherus Biosciences, Inc. is a biopharmaceutical company based in Redwood City, California, specializing in the development and commercialization of innovative biologic therapies. The company focuses on creating stable formulations of recombinant proteins, addressing critical therapeutic areas such as liver disease and lipodystrophy. Coherus is known for its work with key biologics, including Aflibercept, Adalimumab, and Etanercept, aiming to improve patient outcomes through advanced biopharmaceutical solutions.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

76 Patents

#27 in Redwood City, CA

#1,131 in California

#4,844 in US

#9,892 in the World

Redwood City, CA, United States of America

Coherus Biosciences, Inc.

Forward Citations = 762

22 inventors:

Mark Cornell Manning (61 out of 85 patents)

Robert W Payne (35 out of 39 patents)

Brian P Murphy (20 out of 134 patents)

4. Douglas Farrar (6 out of 6 patents)

5. Tsutomu Arakawa (5 out of 20 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Coherus Biosciences, Inc.. Retrieved from https://idiyas.com/company/coherus-biosciences

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…